Drawing for KROMASURE

USPTO serial 99215721

KROMASURE

Reviewed by CopyMark Law Group

Status 688Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
BAYLISS, HUNTER A
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 688: Status 688 means a Notice of Allowance was issued. For intent-to-use applications, you must file a Statement of Use with specimens or request an extension before the deadline — usually six months from the notice date.

Need help with KROMASURE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,844*

Plus Government fees of $900

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Amanda H. Wilcox

Amanda H. Wilcox Taft Stettinius & Hollister LLP200 Public Square, Suite 3500Cleveland, OH 44114United States

Goods and services

ClassDescriptionStatusFirst use
001Assays and reagents for use in genetic research; Assays for research purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays for research purposes other than for medical or veterinary purposes; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific use; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use as reagents for scientific and research use in biotechnology fields; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for research purposesACTIVE—
005Cell growth media for growing cells for medical or clinical use; Cells for medical or clinical use; Cells for medical use; Clinical medical reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Immunoassay reagents for medical use; Culture media for cultivating human blood cells for diagnosing disease for medical purposes; Solutions for medical and clinical use in storing and treating cells, blood and blood components; Stem cells for medical or veterinary use; Stem cells for medical purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs for medical purposes; Diagnostic preparations for medical purposes used by clinical or medical laboratories; Diagnostic reagents for medical purposes used by clinical or medical laboratories; Testing kits containing peptide substrates used in analyzing and detecting certain toxins used by clinical or medical laboratoriesACTIVE—
010Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testingACTIVE—
035Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Business consulting and management in the field of clinical trials, namely, providing information management servicesACTIVE—
042Custom design and development of chemical reagents and biochemical assays; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical research; Medical research in the field of oncology; Medical research services; Scientific research; Scientific research and development; Scientific research consulting; Scientific research in the field of genetics and genetic engineering; Genetic testing for scientific research purposes; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific research for medical purposes in the area of cancerous diseasesACTIVE—
044DNA screening for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (NOAM): A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.

DateCodeEventWhat it means
Sep 29, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 4, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 4, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 29, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 6, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 27, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 30, 2026XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Jan 30, 2026XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Oct 31, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 23, 2025DOCKASSIGNED TO EXAMINER—
Oct 17, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 3, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 3, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance